Loading…
BIIB
Biogen Inc
NASDAQ· Healthcare· Drug Manufacturers - General· CUSIP 09062X103
$253.84+5.34%Price as of Oct 23, 00:41 UTC · updated once a day, after the close
At a glance
Biogen Inc (BIIB) is listed on NASDAQ and classified in Drug Manufacturers - General, part of the Healthcare sector. It is headquartered in Cambridge, United States and has 7,500 employees. The company is worth $37.51B and trades at 45.1x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $9.89B in fiscal 2025, up 2.2% from the year before. Net income was $1.29B. The share price is within 3% of its 52-week high. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $416.93M. In that quarter, 2 of them opened or added to the position and 2 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $37.51B
- P/E
- 45.1x
- Forward P/E
- 15.4x
- P/B
- 2.0x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- $5.63
- ROE
- 4.58%
- Profit margin
- 8.32%
- Revenue growth
- +3.40%
- Beta
- 0.09
- 52-week high
- $254.41
- 52-week low
- $138.00
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
- Cliff AsnessAddedAQR Capital Management · Q2 2026$416.93M1.94M shares · 0.1% of portfolio
Ken GriffinAddedCitadel Advisors · Q2 2026$90.39M418.36K shares · 0.1% of portfolio- Steve CohenReducedPoint72 Asset Management · Q2 2026$19.05M88.15K shares · 0.0% of portfolio
- Renaissance TechnologiesReducedRenaissance Technologies · Q2 2026$16.8M77.74K shares · 0.0% of portfolio
- Two SigmaHeldTwo Sigma Investments · Q2 2026$1.54M7.11K shares · 0.0% of portfolio
Price over time
▼ -1.3% over 5Y.
today you would have $872.39▼ -12.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 19 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $175.99 | $152.92 | $258.77 | $276.92 | $239.92 | $244.86 | $296.73 | $300.92 | $318.57 | $283.58 | $306.35 | $339.45 | $279.57 | $146.37 | $110.05 | $67.05 | $53.50 | $47.63 | $56.92 | |
| P/E | 20.0x | 20.0x | 13.7x | 32.5x | 13.3x | 23.1x | 9.9x | 9.4x | 13.9x | 26.7x | 16.8x | 20.0x | 27.4x | 35.8x | 25.4x | 21.8x | 17.0x | 16.0x | 18.0x | 28.6x |
| P/S | 3.9x | 2.6x | 2.3x | 3.8x | 3.9x | 3.2x | 2.8x | 3.6x | 4.4x | 5.5x | 5.3x | 6.2x | 8.2x | 9.5x | 6.3x | 5.2x | 3.4x | 3.3x | 3.3x | 5.7x |
| P/B | 3.5x | 1.4x | 1.3x | 2.5x | 3.0x | 3.2x | 3.5x | 3.9x | 4.5x | 5.3x | 5.0x | 7.1x | 7.4x | 7.7x | 5.0x | 4.1x | 3.0x | 2.3x | 2.4x | 3.3x |
| EPS | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.93 | $15.34 | $12.37 | $7.81 | $5.76 | $5.04 | $3.94 | $3.35 | $2.65 | $1.99 | |
| Profit margin | 24.45% | 13.07% | 16.87% | 11.81% | 29.95% | 14.17% | 29.76% | 40.96% | 32.93% | 20.69% | 32.34% | 32.95% | 30.25% | 26.86% | 25.02% | 24.45% | 21.31% | 22.16% | 19.11% | 20.12% |
| ROE | 19.82% | 7.08% | 9.76% | 7.85% | 22.74% | 14.28% | 37.39% | 44.13% | 33.98% | 20.13% | 30.50% | 37.84% | 27.15% | 21.60% | 19.82% | 19.21% | 18.63% | 15.59% | 13.49% | 11.49% |
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$127.14
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$136.73
Median P/E of 24.3 among peers in the sector.
Earnings
$112.43
Median P/E of 20.0 across this company’s own years on record.
Cash flow
$206.76
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
How the average is calculated
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
Earnings $125.43 (avg. of 3)+Cash flow $206.76÷ 2 =$166.10
$166.10
4 methods answered, across 2 families.
$124.57
Room for errors in the reported numbers.
$253.84
-34.6% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| RPRXRoyalty Pharma plc | $63.75 | 33.0x | 4.2x | 1.47% | 13.96% | $36.84B |
| RMDResmed Inc | $253.06 | 23.6x | 5.5x | 1.04% | 24.27% | $35.59B |
| CNCCentene Corp | $71.24 | — | 1.6x | 0.00% | -20.36% | $35.19B |
| RVMDRevolution Medicines, Inc. | $187.69 | — | 15.4x | 0.00% | -79.09% | $40.23B |
| ILMNIllumina Inc | $269.40 | 50.3x | 14.3x | 0.00% | 32.34% | $40.68B |
| ALCAlcon Inc | $70.63 | 51.2x | 1.6x | 0.51% | 2.94% | $34.14B |
About the company
- 7,500
- Cambridge, United States